Efficacy and safety of Nivolumab in pretreated patients with advanced non small cell lung cancer patients

Trial Profile

Efficacy and safety of Nivolumab in pretreated patients with advanced non small cell lung cancer patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top